GlobeNewswire

Vistagen Provides Regulatory Update Following Productive Type C Meeting with U.S. FDA on Phase 3 Development of Fasedienol for Social Anxiety Disorder
09/11/2026
Constructive feedback from FDA clarifies potential Phase 3 development path forward SOUTH SAN FRANCISCO, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company [...]
Celcuity Announces FDA Acceptance of sNDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer
09/11/2026
FDA assigned a PDUFA goal date of June 25, 2027 MINNEAPOLIS, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a commercial-stage biotechnology company focused on developing and commercializing targeted [...]
Polaryx Therapeutics Activates First Clinical Trial Site for SOTERIA Phase 2 Basket Trial of PLX-200
09/11/2026
Boys Town National Research Hospital in Nebraska becomes first activated site in study targeting four rare pediatric lysosomal storage disorders and has now initiated patient screening as Polaryx advances toward first [...]
Pliant Therapeutics Announces Presentation of PLN-101095 Preclinical and Clinical Data at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer
09/11/2026
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced the presentation of preclinical proof-of-concept data and new clinical biomarker analyses related [...]
Veru to Present New Results on Effects of Enobosarm on Physical Function in Older Patients Receiving GLP-1 RA from the Phase 2b QUALITY clinical study at ObesityWeek 2026
09/11/2026
MIAMI, FL, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of metabolic diseases and oncology, [...]
Biodexa provides R&D Update
09/11/2026
November 9, 2026 Biodexa provides R&D Update Phase 3 Serenta trial in FAP is now two-thirds recruited Preparations advanced for Phase 1 trial of MTX240 in GIST Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” [...]
Vireo Growth Inc. Completes Acquisition of FLUENT Corp.
09/11/2026
Transaction further strengthens Vireo’s position in Florida and adds FLUENT’s Buffalo, New York operations MINNEAPOLIS and TAMPA, Fla., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Vireo Growth Inc. (CSE: VREO; OTCQX: VREOF) (“ [...]
NeOnc CEO Adds Another 70,000 Shares as Insider Buying Continues
09/11/2026
DALLAS, Nov. 09, 2026 (GLOBE NEWSWIRE) -- ( www.InvestorsTape.com ) — NeOnc Technologies Holdings (NASDAQ:NTHI) CEO Amir Heshmatpour has purchased another 70,000 shares of the company's common stock for approximately $ [...]
Cannabix Technologies Announces Detection of Fentanyl in Human Breath
09/11/2026
Successful detection of fentanyl in human breath marks a significant technical milestone VANCOUVER, British Columbia, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: [...]
Curia Expands Fermentation Capacity in León, Spain
09/11/2026
The 5-million-euro investment will strengthen fermentation and downstream processing operations ALBANY, N.Y., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Curia Global Inc. (Curia), a global contract research, development and [...]
Curia augmente sa capacité de fermentation à León, en Espagne
09/11/2026
Cet investissement de 5 millions d’euros renforcera les opérations de fermentation et de traitement en aval ALBANY, New York, 09 nov. 2026 (GLOBE NEWSWIRE) -- Curia Global Inc. (Curia), une organisation mondiale de [...]
LifeStance Health Group Announces Pricing of Secondary Public Offering
09/11/2026
SCOTTSDALE, Ariz., Nov. 09, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (“LifeStance” or the “Company”) (Nasdaq: LFST), one of the nation’s largest providers of virtual and in-person outpatient mental health [...]
NewcelX Announces Pricing of $1.55 Million Equity Financing at 20% Premium Pricing to Market
09/11/2026
The financing led by international healthcare investors, alongside The Crushing T1 Foundation, reinforces confidence in NewcelX’s strategy and long-term potential ZURICH, Nov. 09, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. ( [...]
HealthEx is Among the First Consumer Health Apps to Support MyChart Central’s Community Authorization for Single-Login Access to Epic Records
09/11/2026
Individuals can now sign in once with their Epic ID to access and share records from their linked health systems and build a more complete health history in HealthEx Wallet SAN FRANCISCO, Nov. 09, 2026 (GLOBE NEWSWIRE [...]
OneMedNet Reports $18.76 Million in Year-to-Date of Contracted Bookings and Publishes “OneMedNet by the Numbers” Growth Recap
09/11/2026
Contracted Demand Now Stands at Nearly 14 Times Full-Year 2025 Bookings, with Roughly Half of 2026 Contracts from New Customers MINNEAPOLIS, Nov. 09, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“ [...]
Capricor’s HOPE-3 Phase 3 Cardiac Results for Deramiocel Win American Heart Association Outstanding Research Award in Pediatric Cardiology
09/11/2026
SAN DIEGO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today [...]
Daré Bioscience Releases Next Episode in “CEO Corner” Video Series
09/11/2026
Sabrina Martucci Johnson, Founder, President and CEO, discusses numerous potential value drivers expected to power the Company’s next phase of growth and commercial success Access the CEO Corner here SAN DIEGO, Nov. 09 [...]
Transactions in connection with and conclusion of share buy-back program
09/11/2026
Company announcement no. 45 - 26 09 November 2026 Transactions in connection with and conclusion of share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as [...]
Nxera’s President & CEO to Participate in a ‘Fireside Chat’ at the Jefferies London Healthcare Conference 2026
09/11/2026
Tokyo, Japan and Cambridge, UK, 9 November 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces its President & CEO, Chris Cargill, will participate in a ‘Fireside Chat’ at the Jefferies [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum